Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Minoru Inomata,1 Yasuhiko Nishioka,2 Arata Azuma11Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo, 2Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, JapanAbstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of t...
Source: Core Evidence - August 26, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Effect of nintedanib in idiopathic pulmonary fibrosis
Inomata M, Nishioka Y, Azuma A (Source: Core Evidence)
Source: Core Evidence - August 26, 2015 Category: Drugs & Pharmacology Source Type: research
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
(Source: Core Evidence)
Source: Core Evidence - August 21, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
Luigi Celio, Monica Niger, Francesca Ricchini, Francesco Agustoni Medical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Introduction: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron is effective in the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy (HEC and MEC, respectively). In addition, palonosetron has been the first and, at present, the only 5-HT3 receptor antagonist to have a specific indication for the prevention of delayed CINV associated with...
Source: Core Evidence - August 21, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Review of palonosetron for CINV control
Celio L, Niger M, Ricchini F, Agustoni F (Source: Core Evidence)
Source: Core Evidence - August 20, 2015 Category: Drugs & Pharmacology Source Type: research
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
(Source: Core Evidence)
Source: Core Evidence - April 27, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Tushar Acharya, Prakash Deedwania Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, Fresno, CA, USA Abstract: Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with warfarin for stroke prevention. Although effective, warfarin use is fraught with mul...
Source: Core Evidence - April 27, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Edoxaban for stroke prevention in atrial fibrillation
Acharya T, Deedwania P (Source: Core Evidence)
Source: Core Evidence - April 27, 2015 Category: Drugs & Pharmacology Source Type: research
Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - April 20, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
David J Hellerstein,1,2 Joseph Flaxer11Department of Psychiatry, Columbia University, 2New York State Psychiatric Institute, New York, NY, USAIntroduction: It has clearly been demonstrated that depressive disorders constitute a major worldwide public health problem, with massive economic and quality-of-life consequences. Existing pharmacological treatments have limited efficacy, with only about a third of patients achieving remission on any one medication. Delayed onset of action and variable tolerability contribute to this limited efficacy. Vilazodone, introduced in the US in 2011, has been described as the first member o...
Source: Core Evidence - April 20, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Vilazodone in depression
Hellerstein DJ, Flaxer J (Source: Core Evidence)
Source: Core Evidence - April 19, 2015 Category: Drugs & Pharmacology Source Type: research
